POSCOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
POSITRON CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.70+0.15 (+9.68%)
Close on Oct 19, 2026
- Market cap
- $55.84M
- P/E (TTM)
- –
- Dividend yield
- –
POSITRON CORP revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q2 25 | Q1 25 | Q3 15 | Q2 15 | Q1 15 | Q4 14 | Q3 14 | Q2 14 | Q1 14 | Q4 13 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radiopharmaceuticals | – | – | – | – | $0 | $0 | $0 | $12.00K | $5.00K | $0 | $0 | $0 | – | – |
| Medical equipment and service | – | – | – | – | $304.00K | $328.00K | $346.00K | $247.00K | $391.00K | $355.00K | $456.00K | $476.00K | – | – |
| Radiopharmaceuticals/Radioisotopes | – | – | – | – | – | – | – | – | – | – | $0 | – | – | – |
| Operating income | Q2 26 | Q1 26 | Q2 25 | Q1 25 | Q3 15 | Q2 15 | Q1 15 | Q4 14 | Q3 14 | Q2 14 | Q1 14 | Q4 13 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radiopharmaceuticals | – | – | – | – | -$105.00K | -$121.00K | -$147.00K | -$37.00K | -$107.00K | -$160.00K | -$203.00K | -$319.00K | – |
| Medical equipment and service | – | – | – | – | -$65.00K | -$102.00K | -$384.00K | -$448.00K | -$600.00K | -$547.00K | -$482.00K | -$867.00K | – |
| Unallocated | – | – | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | – |
| Radiopharmaceuticals/Radioisotopes | – | – | – | – | – | – | – | – | – | – | -$203.00K | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Positron's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.